Lactoferrin Treatment in HIV Patients

• Status: Completed
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Our general goal is to evaluate the potential effectiveness of recombinant lactoferrin (1500mg bid) for reducing inflammation among HIV positive participants.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jason Baker
• Collaborator: Ventria Bioscience
• Treatments: Lactoferrin

Criteria

Inclusion Criteria:

1. HIV-positive participants receiving Antiretroviral Therapy (ART) for >1 year

2. HIV RNA level <200 copies/mL for at least 6 months (≥2 separate values)

3. Age >40 years

Exclusion Criteria:

1. Prior cardiovascular disease or stroke

2. Diabetes

3. Rheumatologic Diseases

4. Pregnancy

5. Chronic kidney disease, stage IV or V (creatinine clearance <30 mL/min/1.73m2)

6. Cirrhosis or end-stage liver disease